Tag:
Aduro
Latest Headlines
Latest Headlines
Aduro swings for the fences with $119M IPO
Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
Cancer vaccine maker Aduro files for $86M IPO
Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.
Aduro, BMS cancer vaccine combo to start Phase II
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
Cancer vaccine partners J&J;, Aduro add $817M pact
Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J; is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo
Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
Aduro licenses BioSante cancer vaccines
Aduro BioTech has gained access to BioSante Pharmaceuticals' GVAX pancreas cancer vaccine and GVAX prostate cancer vaccine through a licensing agreement. The Berkeley, CA-based company plans to
